Table 1.
Humoral immunogenicity outcomes against wild-type SARS-CoV-2 after the third dose of CoronaVac in evaluable analysis population.
| Adolescents 3 doses |
Adults 3 doses |
|
|---|---|---|
| S IgG on ELISA | ||
| N | 56 | 49 |
| GM OD450 value (95% CI) | 0.93 (0.83-1.04) | 0.91 (0.83-1.00) |
| % positive (>/=LOD at 0.3) | 98.2%, P>0.9999 | 100% |
| S-RBD IgG on ELISA | ||
| N | 60 | 119 |
| GM OD450 value (95% CI) | 1.77 (1.68-1.87) | 1.62 (1.53-1.73) |
| % positive (>/=LOD at 0.5) | 100%, P>0.9999 | 99.2% |
| S-RBD ACE2-blocking antibody on sVNT | ||
| N | 60 | 119 |
| GM % inhibition (95% CI) | 84.9% (81.3-88.6%) | 76.9% (71.8-82.3%) |
| % positive (>/=LOQ at 30%) | 100%, P=0.30 | 96.6% |
| Neutralizing antibody on PRNT | ||
| N | 60 | 22 |
| GM PRNT90 (95% CI) | 17.8 (13.7-23.3) | 12.1 (8.68-16.8) |
| % positive (>/=LOD at 10) | 78.3%, P=0.57 | 72.7% |
| GM PRNT50 (95% CI) | 55.3 (43.2-70.7) | 32.1 (21.1-48.7) |
| % positive (>/=LOD at 10) | 100%, P=0.27 | 95.5% |
| S IgG avidity on ELISA | ||
| N | 55 | 49 |
| GM avidity index (95% CI) | 38.5% (34.6-42.8) | 32.1% (29.4-35.0) |
| S IgG FcγRIIIa-binding on ELISA | ||
| N | 56 | 49 |
| GM OD450 value (95% CI) | 1.41 (1.21-1.63) | 1.47 (1.23-1.77) |
| % positive (>/=LOD at 0.28) | 98.2%, P=0.60 | 95.9% |
| N IgG on ELISA | ||
| N | 60 | 22 |
| GM OD450 value (95% CI) | 2.82 (2.62-3.04) | 2.08 (1.72-2.52) |
| % positive (>/=LOD at 0.88) | 98.3%, P=0.47 | 95.5% |
| N-CTD IgG on ELISA | ||
| N | 60 | 22 |
| GM OD450 value (95% CI) | 2.97 (2.77-3.17) | 1.96 (1.61-2.38) |
| % positive (>/=LOD at 1.34) | 98.3%, P=0.17 | 90.9% |
S, spike protein; ELISA, enzyme-linked immunosorbent assay; GM, geometric mean; OD, optical density; LOD, limit of detection; LOQ, limit of quantification; CI, confidence interval; RBD, receptor-binding domain; ACE-2, angiotensin-converting enzyme-2; sVNT, surrogate virus neutralization test; PRNT, plaque reduction neutralization test; PRNT90, 90% plaque reduction neutralization titre; PRNT50, 50% plaque reduction neutralization titre; FcγRIIIa, Fc gamma receptor III-a; N, nucleocapsid protein; CTD, C-terminal domain. P-values compare the proportion of positive responses between adolescents and adults by Fisher’s exact test.